GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » E10

Predictive Oncology (Predictive Oncology) E10 : $-2,032.04 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Predictive Oncology's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.040. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2,032.04 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was 46.90% per year. During the past 5 years, the average E10 Growth Rate was 39.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Predictive Oncology was 46.90% per year. The lowest was 33.10% per year. And the median was 37.70% per year.

As of today (2024-06-10), Predictive Oncology's current stock price is $1.21. Predictive Oncology's E10 for the quarter that ended in Mar. 2024 was $-2,032.04. Predictive Oncology's Shiller PE Ratio of today is .


Predictive Oncology E10 Historical Data

The historical data trend for Predictive Oncology's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology E10 Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20,304.60 -15,723.40 -9,654.71 -4,900.18 -2,350.18

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,131.89 -3,704.17 -2,843.62 -2,350.18 -2,032.04

Competitive Comparison of Predictive Oncology's E10

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Shiller PE Ratio falls into.



Predictive Oncology E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Predictive Oncology's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.04/131.7762*131.7762
=-1.040

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

per share eps CPI Adj_EPS
201406 -2,922.480 100.560 -3,829.706
201409 -1,861.800 100.428 -2,442.958
201412 -3,827.500 99.070 -5,091.097
201503 -359.546 99.621 -475.598
201506 -1,790.520 100.684 -2,343.452
201509 -1,073.460 100.392 -1,409.048
201512 -2,173.880 99.792 -2,870.616
201603 -602.000 100.470 -789.579
201606 -190.000 101.688 -246.218
201609 -64.000 101.861 -82.796
201612 -32.108 101.863 -41.537
201703 -42.000 102.862 -53.806
201706 -82.000 103.349 -104.555
201709 -32.000 104.136 -40.494
201712 -32.000 104.011 -40.542
201803 -30.000 105.290 -37.547
201806 -40.000 106.317 -49.579
201809 -37.800 106.507 -46.768
201812 -48.400 105.998 -60.171
201903 -41.800 107.251 -51.359
201906 4.800 108.070 5.853
201909 -26.200 108.329 -31.871
201912 -90.800 108.420 -110.360
202003 -18.600 108.902 -22.507
202006 -7.200 108.767 -8.723
202009 -9.200 109.815 -11.040
202012 -11.583 109.897 -13.889
202103 -2.200 111.754 -2.594
202106 -1.000 114.631 -1.150
202109 -1.600 115.734 -1.822
202112 -2.600 117.630 -2.913
202203 -1.020 121.301 -1.108
202206 -2.890 125.017 -3.046
202209 -1.040 125.227 -1.094
202212 -2.030 125.222 -2.136
202303 -0.860 127.348 -0.890
202306 -0.980 128.729 -1.003
202309 -0.780 129.860 -0.792
202312 -0.850 129.419 -0.865
202403 -1.040 131.776 -1.040

Add all the adjusted EPS together and divide 10 will get our e10.


Predictive Oncology  (NAS:POAI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Predictive Oncology E10 Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (Predictive Oncology) Business Description

Traded in Other Exchanges
N/A
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Executives
Robert L Myers officer: CHIEF FINANCIAL OFFICER 4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr director 633 1ST STREET WEST, SONOMA CA 95476
Veena Rao director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr director 1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch director P O BOX 1572, PEPPERELL MA 01463
Pamela Bush officer: Chief Business Officer 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley director 1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith director 151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle director 1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz 10 percent owner 20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel director 900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior director 2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121